[New considerations in the surgical treatment of pancreatic neuroendocrine tumours].
Except insulinomas, pancreatic neuroendocrine tumours are malignant in more than 50% of cases. Treatment of these tumours should be directed against the tumours and the excess of hormones produced by the tumours. Surgical treatment may reduce the mortality and morbidity of patients and, in case of localized lesions, may result in a definitive cure. The aim of this review is to summarize novel developments in the surgical treatment of pancreatic neuroendocrine tumours, including those related to metastatic diseases and MEN1 syndrome.
Szegedi Tudományegyetem, Általános Orvostudományi Kar Sebészeti Klinika Szeged Szőkefalvi-Nagy B. u. 6. 6720.
Gyula
G
Farkas
D015408:Gastrinoma / Q000601:surgery; D005935:Glucagonoma / Q000601:surgery; D006801:Humans; D007340:Insulinoma / Q000601:surgery; D018761:Multiple Endocrine Neoplasia Type 1 / Q000601:surgery; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000601:surgery*; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000601:surgery*; D013005:Somatostatinoma / Q000601:surgery; D003969:Vipoma / Q000601:surgery